Antioxidant Micronutrients in Malaria
NCT01152931 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2012-05-31
Summary
In the last decade, the prevalence of malaria has been escalating at an alarming rate, especially in Africa. An estimated 300 to 500 million cases each year cause 1.5 to 2.7 million deaths, more than 90% occur in children under 5 years of age in Africa (WHO 1995). Malaria is Africa's leading cause of under-five mortality (20%) and constitutes 10% of the continent's overall disease burden. It accounts for 40% of public health expenditure, 30-50% of inpatient admissions, and up to 50% of outpatient visits in areas with high malaria transmission. Antioxidant micronutrients have immunomodulatory role and may have suppressive activity.
Conditions
Interventions
- DRUG
-
Amodiaquine + Artesunate
Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
- DRUG
-
Amodiaquine + Artesunate
Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
- DRUG
-
Lumefantrine + Artemether
Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
- DIETARY_SUPPLEMENT
-
Artesunate + vitamin A
Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
- DIETARY_SUPPLEMENT
-
Artesunate + vitamin E
Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
- DIETARY_SUPPLEMENT
-
Artesunate + Zinc
Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
- DIETARY_SUPPLEMENT
-
Artesunate + selenium
Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
- DIETARY_SUPPLEMENT
-
Amodiaquine + vitamin A
Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
- DIETARY_SUPPLEMENT
-
Amodiaquine + Vitamin E
Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
- DIETARY_SUPPLEMENT
-
Amodiaquine + Zinc
Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
- DIETARY_SUPPLEMENT
-
Amodiaquine + Selenium
Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if \> 1year. 50ug daily for 4 days if \< 1 year.
- DIETARY_SUPPLEMENT
-
Artesunate + vitamin A + vitamin E
Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if \< 1 year. 10,000 IU orally daily for 4 days if \> 1 year.
- DIETARY_SUPPLEMENT
-
Artesunate + Vitamin A + Zinc
Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if \> 1 year. All administered orally.
- DIETARY_SUPPLEMENT
-
Artesunate + Vitamin A + Selenium
Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if \> 1 year.
- DIETARY_SUPPLEMENT
-
Artesunate + Vitamin E + Selenium
Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if \> 1 year. 50 ug orally daily for 4 days if \< 1 year.
- DIETARY_SUPPLEMENT
-
Artesunate + Vitamin E + Zinc
Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if \< 1 year. 25 mg orally daily for 4 days if \> 1 year.
Sponsors & Collaborators
-
University of Lagos, Nigeria
lead OTHER
Principal Investigators
-
Osede Ignis Iribhogbe, MB.BS, M.Sc · Department of Pharmacology and Therapeutics, College of Medicine, Ambrose Alli University, Ekpoma
-
Ibrahim Oreagba, B.Pharm, M.Sc, Ph.D · Deparment of Pharmacology, College of Medicine, University of Lagos, Nigeria
-
Elizabeth O. Agbaje, B.Sc, M.Sc, MPhil, Ph.D · Department of Pharmacology, College of Medicine University of Lagos, Nigeria
-
Prof. Onyebiguwa Patrick NMORSI, PhD, MD · Dean, Faculty of Natural Sciences Ambrose Alli University Ekpoma
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 6 Months
- Max Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-08-31
- Primary Completion
- 2010-11-30
- Completion
- 2010-12-31
Countries
- Nigeria
Study Locations
More Related Trials
-
Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate
NCT00238017 ·Status: UNKNOWN ·Phase: PHASE4
-
Treatment of Uncomplicated Childhood Malaria in Tanzania by Artemether+Lumefantrine - Efficacy and Genotyping
NCT00336375 ·Status: COMPLETED ·Phase: PHASE4
-
Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children
NCT01082705 ·Status: COMPLETED ·Phase: PHASE3
-
Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania
NCT00885287 ·Status: COMPLETED ·Phase: PHASE4
-
In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso
NCT00808951 ·Status: COMPLETED ·Phase: PHASE4
-
"Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"
NCT03241901 ·Status: COMPLETED ·Phase: PHASE4
-
Antimalarial Drug Resistance in Mali
NCT00127998 ·Status: COMPLETED ·Phase: NA
-
A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children
NCT00132548 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers
NCT00791531 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique
NCT06970600 ·Status: COMPLETED ·Phase: NA
-
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children
NCT02168569 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.
NCT02089841 ·Status: COMPLETED ·Phase: PHASE4
-
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria
NCT01228344 ·Status: COMPLETED
-
Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children
NCT01407887 ·Status: COMPLETED ·Phase: PHASE2
-
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria
NCT00529867 ·Status: COMPLETED ·Phase: PHASE4
-
Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers
NCT02230579 ·Status: COMPLETED ·Phase: PHASE1
-
Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi
NCT00164359 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria
NCT00425763 ·Status: COMPLETED ·Phase: PHASE4
-
Phase 1b Malaria Clinical Trial Using Argemone Mexicana in Healthy Adults in Mali
NCT01645254 ·Status: UNKNOWN ·Phase: PHASE1
-
In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure
NCT02590627 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde
NCT04565184 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Artesunate-amodiaquine (AS-AQ) in Children With Malaria and Severe Acute Malnutrition, Madaoua, Niger 2010
NCT01204411 ·Status: WITHDRAWN ·Phase: PHASE4
-
Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
NCT00297882 ·Status: COMPLETED ·Phase: PHASE3
-
In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria
NCT02637128 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
NCT03923725 ·Status: COMPLETED ·Phase: PHASE3